Curaleaf management commentary attributes narrower Q3 2026 net loss from continuing operations to lower tax provision
Curaleaf reported Q3 2026 revenue up 11% to $352.65 million and a net loss of $32.72 million, down from $56.68 million, primarily reflecting a lower tax provision and improved discontinued operations.
1. Q3 results
Third-quarter 2026 revenue rose 11% to $352.65 million, attributed to retail expansion and stronger wholesale distribution. International revenue increased 28% to $58.7 million, driven by patient growth and flower and vape sales in Germany and Britain.
2. Margins and expenses
Gross margin fell to 48% from 51%, reflecting product-mix changes, including the balance of wholesale versus retail sales. Operating expenses increased 9% to $167.53 million, primarily reflecting higher compensation costs and professional fees.
3. Net loss narrows
Net loss narrowed to $32.72 million from $56.68 million, primarily reflecting a lower tax provision and improved discontinued operations.
